The future of long-lasting relief: Lasting Effect Buccal Extended-Release Delivery System

Lasting Effect Consumer Pharma

We are a consumer driven, pharma company, devoted to research and development of beneficial products based on our novel Buccal Extended Release Drug Delivery System.

our supporters

Buccal and Transmucosal delivery Technology

Delivering drugs topically (locally) / systemically through the oral mucosa.
Many advantages compered to Oral Trans digestive delivery.
Facilitates population with Dysphagia / salivation problems.
The main challenge with Buccal delivery is low compliance due to administration difficulties.

First product -Gingivitis treatment buccal extended release tablet

After extensive testing for the API that gives the best results, Lasting Effect developed an anti-inflammatory and antibacterial API. We successfully in vitro tested our tablet on Gingivitis causing bacteria. Our buccal tablet inhibited 93-96% of Gingival bacteria.

Second product - PARKINSON LATE MOTOR COMPLICATIONS

Parkinson’s symptoms arise from dopamine declines and affect patients in late stage of Parkinson disease.
The current solution for late-stage Parkinson motor complications: An invasive device/pump for continuous and prolonged delivery of L-DOPA and Carbidopa to a Parkinson’s patient with the goal to receive continuous dopaminergic stimulation.
Our solution: Buccal extended-release tablet loaded with our researched API for continuous dopamine secretion.

Investors Opportunity

Existing markets
Major improvement of existing treatments
Product Market Fit
Experienced team
Clinically proven
Novelty and patentability
Future pipeline
High feasibility for success